Luopu Biological-B (02157): The registration clinical study results of MRG003 will be announced in the form of LBA at the 2025 ASCO Annual Meeting.

Chinatong Finance APP News, Lepu Biotechnology-B(02157) announced that the key registration clinical research results of the company's independently developed candidate drug MRG003 (an innovative antibody drug conjugate ("ADC") targeting epidermal growth factor receptor, for the treatment of recurrent or metastatic nasopharyngeal carcinoma ("R/M NPC")) will be released in the form of "Late Breaking Abstract (LBA)" at the American Society of Clinical Oncology ("ASCO") Annual Meeting in 2025, with an oral presentation at the meeting.